Dual incretin agonist (revision 26)

A dual incretin agonist is a single engineered peptide that activates two receptors of the glucagon-secretin family — most often the receptor for Glucose-dependent insulinotropic polypeptide and the GLP-1 receptor — in a ratio fixed by its chemistry rather than by a prescriber's choice of two drugs.^[1]

The approach differs fundamentally from co-administration of two agents. A single molecule delivers both activities to the same tissues with identical pharmacokinetics, so the ratio at the receptor does not drift with differential clearance. The price is that the ratio cannot be adjusted: it is a property of the molecule, and changing it means changing the drug.^[2]

Tirzepatide is the only member marketed to date. Why dual agonism outperforms GLP-1 monotherapy is not settled, and the leading explanations — adipose-tissue GIP action, central GIP effects that improve tolerability, and restoration of beta-cell GIP responsiveness under ambient GLP-1 signalling — have not been separated by any published trial.^[3]

The receptors of this family share a common architecture — a large extracellular domain capturing the C-terminal helix of the ligand, and a transmembrane bundle engaged by the ligand N-terminus — and roughly 40–50% sequence identity in the transmembrane region. That relatedness is what makes a single ligand for two of them possible.^[1]

The design proceeds by choosing a backbone, then substituting residues that confer activity at the second receptor while retaining activity at the first. In practice a GIP backbone has proved more tolerant of the substitutions needed for GLP-1 activity than the reverse, which is why tirzepatide is built from GIP rather than from GLP-1.^[2]

Reported potency ratios are assay-dependent — cell line, readout, incubation time and receptor expression level all move them — and cross-publication comparison of ratios is unreliable. A ratio quoted without its assay system is not a meaningful number.

Three explanations circulate, and they are not mutually exclusive.

1. Adipose GIP action. GIP receptors are expressed on adipocytes, where GIP promotes triglyceride storage. Whether the clinical benefit arises from agonism or from functional antagonism through receptor desensitisation is genuinely disputed, and — awkwardly for the field — GIP-receptor antagonists have also produced weight loss in early studies.
2. Improved tolerability. If GIP-receptor agonism in the area postrema reduces nausea, a dual agonist can be escalated to a total exposure that a GLP-1 agonist alone could not reach. On this account the benefit is not a new mechanism but a higher tolerable dose.
3. Restored beta-cell responsiveness. Beta-cell responsiveness to GIP is impaired in type 2 diabetes but is partly restored when glycaemia improves, so a dual agonist may create the conditions for its own GIP component to work.

None of the three has been isolated experimentally in humans. The trials were designed to establish efficacy, not to partition it.^[3]

Other pairings exist. Glucagon/GLP-1 dual agonists — survodutide, efinopegdutide — pair the energy-expenditure and hepatic-fat effects of glucagon-receptor agonism with the appetite and glycaemic effects of GLP-1 agonism, with the GLP-1 component dosed to dominate the glycaemic balance. See Glucagon.

Amylin/GLP-1 pairing is achieved differently: CagriSema is a co-formulation of two separate peptides rather than one molecule, which reintroduces the possibility of differential pharmacokinetics but allows the ratio to be chosen at formulation.

Adding a third receptor gives the triple agonists, of which retatrutide is the most advanced. Each additional receptor multiplies the design constraints, and the tolerability window narrows as more pathways are engaged simultaneously.^[1][4]

• Tirzepatide
• Retatrutide
• Triple agonist
• Glucose-dependent insulinotropic polypeptide
• CagriSema
• Survodutide